Trial | NCT00132119  Report issue

Title

Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nalmefene ...

  • Study Participants

    233
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.
Study Started
Aug 31
2005
Primary Completion
Aug 31
2006
Study Completion
Aug 31
2006
Last Update
May 19
2008
Estimate

Drug nalmefene HCl

Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.

Other Placebo

Placebo tablet

1 Experimental

Nalmefene HCl 20 mg

2 Experimental

Nalmefene HCl 40 mg

3 Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

Current diagnosis of pathological gambling as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
No Results Posted